Immunic presents additional data on multiple sclerosis drug candidate

May 28, 2026 6:30 AM

Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found